CLEC2D and breast carcinoma: Targeting Induction of Lectin-like Transcript 1 (LLT1), a ligand on breast tumors that interacts with NK cell receptors, through antibody blocking or gene knockdown disrupts this interaction, thereby augmenting the destruction of breast cancer cells by NK cells (36, 57).